Skip to main content
Download PDF

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Alzheimer's Research & Therapy volume 16, Article number: 34 (2024) Cite this article

Abstract

Background

Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synaptic dysfunction is an early feature in bvFTD and identification of specific biomarkers might improve its diagnostic accuracy. Our goal was to understand the differential diagnostic potential of cerebrospinal fluid (CSF) synaptic biomarkers in bvFTD versus PPD and their specificity towards bvFTD compared with Alzheimer’s disease (AD) and controls. Additionally, we explored the association of CSF synaptic biomarkers with social cognition, cognitive performance, and disease severity in these clinical groups.

Methods

Participants with probable bvFTD (n = 57), PPD (n = 71), AD (n = 60), and cognitively normal controls (n = 39) with available CSF, cognitive tests, and disease severity as frontotemporal lobar degeneration-modified clinical dementia rating scale (FTLD-CDR) were included. In a subset of bvFTD and PPD cases, Ekman 60 faces test scores for social cognition were available. CSF synaptosomal-associated protein 25 (SNAP25), neurogranin (Ng), neuronal pentraxin 2 (NPTX2), and glutamate receptor 4 (GluR4) were measured, along with neurofilament light (NfL), and compared between groups using analysis of covariance (ANCOVA) and logistic regression. Diagnostic accuracy was assessed using ROC analyses, and biomarker panels were selected using Wald’s backward selection. Correlations with cognitive measures were performed using Pearson’s partial correlation analysis.

Results

NPTX2 concentrations were lower in the bvFTD group compared with PPD (p < 0.001) and controls (p = 0.003) but not compared with AD. Concentrations of SNAP25 (p < 0.001) and Ng (p < 0.001) were elevated in patients with AD versus those with bvFTD and controls. The modeled panel for differential diagnosis of bvFTD versus PPD consisted of NfL and NPTX2 (AUC = 0.96, CI: 0.93–0.99, p < 0.001). In bvFTD versus AD, the modeled panel consisted of NfL, SNAP25, Ng, and GluR4 (AUC = 0.86, CI: 0.79–0.92, p < 0.001). In bvFTD, lower NPTX2 (Pearson’s r = 0.29, p = 0.036) and GluR4 (Pearson’s r = 0.34, p = 0.014) concentrations were weakly associated with worse performance of total cognitive score. Lower GluR4 concentrations were also associated with worse MMSE scores (Pearson’s r = 0.41, p = 0.002) as well as with worse executive functioning (Pearson’s r = 0.36, p = 0.011) in bvFTD. There were no associations between synaptic markers and social cognition or disease severity in bvFTD.

Conclusion

Our findings of involvement of NTPX2 in bvFTD but not PPD contribute towards better understanding of bvFTD disease pathology.

Background

Frontotemporal dementia (FTD) is a clinically, genetically, and pathologically heterogeneous disease and the second most common form of young-onset dementia after Alzheimer’s disease (AD) [1]. The most prevalent form is the behavioral variant of FTD (bvFTD), which is characterized by slowly progressive behavioral symptoms and impaired social cognition. In 30% of the bvFTD patients, the disease is caused by a pathogenic mutation (C9ORF72, MAPT, GRN), but the majority of cases are denoted sporadic bvFTD (70%) [2]. The lack of an early, disease-specific molecular biomarker in sporadic bvFTD together with its significant overlap in clinical symptoms with primary psychiatric disorders (PPD) and frontotemporal hypometabolic patterns on [18F]-2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography ([18F]FDG-PET) scans hampers diagnostic distinction. This leads to misdiagnosis in 50% of the cases with an average diagnostic delay of 6.4 years [3,4,5].

Evidence from post-mortem and clinical studies including pre-dementia stages show that loss of synaptic function is a predominant early feature in bvFTD and correlates with the level of cognitive impairment [6,7,8,9,10,11,12,13,14]. In accordance, a recent in vivo study using the [11C]UCB-J PET tracer to detect synaptopathy showed widespread frontotemporal loss of synapses in symptomatic bvFTD patients, which is related to disease severity [14]. Also, lower brain synaptic densities on [18F]UCB-H PET were found in the temporal brain regions involved in social cognition, highlighting the clinical relevance of synaptopathy in the disease pathophysiology of FTD [11].

In agreement, using cerebrospinal fluid (CSF) biomarkers as indicators for synapse health, differential synaptic concentrations were found in genetic forms of FTD [12]. Previous studies on synaptic involvement in FTD predominately assessed genetic FTD cases, had a small sample size, or did not include PPD as a control group, whereas the latter is the most challenging to distinguish from bvFTD in clinical practice [10,11,12]. Identification of specific CSF synaptic markers in sporadic bvFTD might improve diagnostic accuracy and aid in a better understanding of FTD pathophysiology. In addition, specific CSF-synaptic panels can provide endpoints in future clinical trials of sporadic bvFTD as they might correlate and reflect cognitive and social functioning.

In an attempt to explore the synaptic pathology in FTD and AD, we recently performed a pilot study where we found that concentrations of CSF synaptic biomarkers synaptosomal-associated protein 25 (SNAP25) and neurogranin (Ng) were elevated in FTD compared with controls, while those of neuronal pentraxin 2 (NPTX2) were lower than in controls, suggesting these could be valuable biomarkers for FTD [15]. SNAP25 is a pre-synaptic vesicle protein involved in neurotransmission, while Ng in the post-synapse regulates calcium ion influxes, and NPTX2 present extracellularly in the synaptic cleft maintains synaptic plasticity [15]. Simultaneously, another recent study suggested that patients with primary psychiatric disorders had significantly lower expression of the post-synaptic protein glutamate receptor 4 (GluR4) in CSF compared with cognitively normal controls and therefore could be useful as biomarkers for PDD [16]. GluR4 is primarily involved in excitatory signal transmission [15]. The axonal protein neurofilament light chain (NfL) has emerged as a promising fluid biomarker to distinguish bvFTD from PPD. Several studies have reported the potential of NfL as a biomarker that correlates with brain atrophy, neurodegeneration, and cognition in dementias [17,18,19,20] and also with other neuronal damage, e.g., due to stroke, amyotrophic lateral sclerosis, and multiple sclerosis [3, 21,22,23,24].

In this study, we aimed to assess the diagnostic performance of CSF synaptic biomarkers in sporadic bvFTD versus PPD and their added value compared with NfL as well as their specificity towards bvFTD compared with AD and controls. Secondly, we assessed the association of CSF synaptic biomarkers with social cognition, cognitive performance, and disease severity in bvFTD.

Methods

Participants

Patients with sporadic probable bvFTD, PPD, AD, and cognitively normal controls who visited the memory clinic of the Alzheimer Center Amsterdam between 2003 and 2021 were included in this study [25,26,27]. We included individuals aged 45–75 years with available CSF in the biobank and available clinical data. Individuals with AD were included in the case of AD-positive CSF biomarkers. BvFTD, PPD, and controls were excluded in the case of AD-positive CSF biomarkers. The study was approved by the Medical Ethical Committee of Amsterdam UMC. All participants provided informed consent and the study has been carried out by the Declaration of Helsinki.

Diagnostic procedure

All participants had an extensive, standardized diagnostic assessment including clinical evaluation by a cognitive neurologist and/or old age psychiatrist, blood examination to exclude somatic causes, administered neuropsychological tests assessing five cognitive domains (attention, memory, speed, executive functioning, visuospatial functioning) [28, 29], lumbar puncture for CSF assessment of the AD biomarkers amyloid-beta42, total tau, and phosphorylated tau181 to determine positive or negative AD biomarkers status (cutoffs applied as published elsewhere), electroencephalography and neuroimaging- magnetic resonance imaging, and, if indicated, a [18F]FDG-PET scan [3, 30]. The diagnosis was concluded in a multidisciplinary meeting using consensus criteria for probable FTD, PPD (DSM-V), and AD [25, 31, 32]. Controls had no evidence of current or recent psychiatric disorders nor a neurodegenerative disorder. Psychiatric diagnoses included mood disorders (n =33), personality disorders (n = 4), autism spectrum disorder (n = 3), anxiety disorder (n = 4), functional disorder (n = 5), schizophrenia (n = 2), and other psychiatry (n = 10) [33]. The psychotropic medications the patients were taking included antidepressants, mood stabilizers (lithium), benzodiazepines, amphetamines (methylphenidate), antiepileptic and antipsychotic drugs, and cholinesterase inhibitors (rivastigmine).

Measures for cognition, disease severity, mood and behavioral symptoms

Participants underwent standardized neuropsychological assessments covering the indicated cognitive domains (memory, attention, executive functioning, language, visuospatial functioning) [29]. For each cognitive domain, at least two tests were used to provide a reliable outcome on cognitive functioning (Table 1) [28]. Per test, a z-score was calculated, and, subsequently, all z-scores covering a specific cognitive domain were averaged into a cognitive domain z-score. Total cognitive score was calculated as an average z-score based on all five cognitive domains (memory, attention, executive functioning, language, visuospatial functioning, Table 1).

Table 1 The cognitive tests included to calculate the z-scores for each cognitive domain [29]
Full size table

A subgroup of the bvFTD group (n = 13) and the PPD group (n = 9) completed a facial emotional recognition test (the Ekman 60 faces test). Disease severity in bvFTD was scaled according to the Frontotemporal Lobar Degeneration-Modified Clinical Dementia Rating (FTLD-CDR) Scale, using the sum-of-boxes score [34]. Also, participants completed the Geriatric Depression Scale (GDS) (mood), the Frontal Assessment Battery (FAB) (behavioral symptoms), and the Mini-Mental State Exam (MMSE) for global cognition. All tests and FTLD-CDR were completed within 12 months of the CSF withdrawal.

CSF biomarker measurements

NfL was measured using a novel ELISA developed at ADx NeuroSciences, described elsewhere [35]. Synaptic protein Ng was measured using a commercial ELISA from EuroImmun, while the other synaptic proteins SNAP25, NPTX2, and GluR4 were measured using novel immunoassays developed and validated as per standardized protocols at ADx NeuroSciences, described in detail elsewhere [15, 36, 37]. The biomarkers are stable up to at least four freeze-thaw cycles in CSF. Thus, we measured SNAP25 and Ng in the first freeze-thaw cycle of the CSF samples, NfL in the second, NPTX2 in the third, and GluR4 in the final fourth freeze-thaw cycle. All clinical duplicate measurements were well within the range of 20% coefficient of variation (CV) for all immunoassays, except GluR4 which had slightly higher variability. The intermediate precision (average %CV) for each immunoassay of quality control samples was as follows: NfL—12%, SNAP25—4%, Ng—11%, NPTX2—15%, and GluR4—25%.

Statistics

All statistical analyses were performed using IBM SPSS Statistics (v.28.0.1.1) or RStudio (v.4.0.3). The demographic differences between the diagnostic groups were assessed using a one-way analysis of variance (ANOVA) or chi-square test where appropriate. The CSF biomarker concentrations and cognitive test scores were log10 transformed to fit a normal distribution. Analysis of covariance (ANCOVA) models corrected for age, sex, and psychotropic medication use with post hoc pairwise comparisons was used to determine differences in biomarker concentrations between the clinical groups, with Bonferroni’s multiple comparison correction. Next, logistic regression analysis was performed to assess the association between the CSF biomarkers and diagnosis for the groups bvFTD versus PPD and bvFTD versus AD while controlling for the effect of age, sex, and psychotropic medication use. Additionally, we used Wald’s backward logistic regression on the biomarkers to select a biomarker panel for the group comparisons between bvFTD and AD or PPD. Receiver operating characteristics (ROC) curves were constructed for the CSF synaptic biomarkers and CSF NfL, as well as for the biomarker panels, not controlling for any potential confounders. For each ROC curve, the sensitivity and specificity were determined at Youden’s indices. Correlation between the CSF synaptic biomarkers and CSF NfL and cognitive test scores were assessed using Pearson’s partial correlation analysis controlling for age. Significance was defined as p < 0.05.

Results

Demographic characteristics

The demographic characteristics of the patients are detailed in Table 2. This cohort included 57 patients with bvFTD (age: 64 ± 8, female: 37%), 71 patients with PPD (age: 56 ± 9, female: 38%), 60 patients with AD (age: 66 ± 7, female: 45%), and 39 controls (age: 57 ± 8, female: 33%). The bvFTD and AD groups were significantly older than the PPD group and controls (p < 0.001 for all). No group differences were found for sex. Thirty percent of patients with bvFTD, 51% of those with PPD, 35% of the AD group, and 15% of the controls used psychotropic medication. Following expectations, psychotropic medication use was more frequent in the PPD group (p < 0.001) than in the control group.

Table 2 Demographic characteristics of the study cohort
Full size table

Among the cognitive domain scores, the bvFTD group scored significantly (p < 0.05) lower than those with PPD for all domains except visuospatial functioning. Furthermore, patients with AD had significantly lower memory (p < 0.001) and visuospatial functioning (p = 0.004) scores than the bvFTD group. As expected, the bvFTD group had lower MMSE scores than PPD (p = 0.018) or controls (p = 0.004), while the AD group had the lowest MMSE scores, the difference being significant compared with PPD (p < 0.001) or controls (p < 0.001) but not bvFTD. Following expectations, the Ekman 60 faces test scores were lower in bvFTD patients compared with PPD patients (p = 0.012) (not available for AD and controls). All bvFTD patients in this cohort had mild to moderate FTD disease severity (FTLD-CDR ≤ 16).

Differential concentrations of candidate CSF biomarkers across the diagnostic groups

The concentrations of the CSF biomarkers are presented in Table 2 and visualized in Fig. 1. Adjusted for age, sex, and psychotropic medication use, we found that NPTX2 concentrations were significantly lower in bvFTD compared with PPD (p < 0.001) and controls (p = 0.005). There was a trend towards lower average NPTX2 concentrations in bvFTD than those in the AD group, although this difference was not significant. SNAP25 and Ng concentrations were higher in AD compared with bvFTD, PPD, and controls (p < 0.001 for all). CSF GluR4 concentrations did not differ between the diagnostic groups. Furthermore, NfL concentrations were higher in bvFTD compared with AD, PPD, and controls (p < 0.001 for all). NfL did not differ between PPD and controls, while patients with AD had higher NfL concentrations compared with PPD and controls (p < 0.001 for both).

Fig. 1
figure 1

Concentrations of candidate CSF biomarkers across the diagnostic groups. Analysis of covariance (ANCOVA) models corrected for age, sex, and psychotropic medication use with post hoc pairwise comparisons were used to determine the log10 transformed biomarker differences between the clinical groups, with Bonferroni’s multiple comparison correction. A SNAP25. B Ng. C NPTX2. D GluR4. E NfL. SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; NfL, neurofilament light. bvFTD, behavioral frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

The logistic regression models for each biomarker controlled for age, sex, and psychotropic medication use, and their predictive value for bvFTD compared with PPD and AD are detailed in Table 3. Of the synaptic biomarkers, only NPTX2 had a significant predictive value for bvFTD versus PPD (odds ratio, OR: 0.997 [0.996, 0.999], p = 0.007). The synaptic biomarkers SNAP25 (OR: 0.966 [0.943, 0.990], p = 0.005) and Ng (OR: 0.998 [0.997, 0.999], p = 0.006) had significant diagnostic values for bvFTD versus AD.

Table 3 Predictive value of the CSF biomarkers for bvFTD versus PPD and AD
Full size table

Diagnostic performance of the candidate CSF biomarkers

We further investigated the diagnostic potential of the CSF biomarkers, stand-alone, as well as statistically selected panels, uncorrected for possible confounders (Table 4, Fig. 2).

Table 4 The AUC of the measured biomarkers as determined using ROC analysis
Full size table
Fig. 2
figure 2

ROC curves showing the differentiation accuracy between the diagnostic groups of biomarkers in CSF. A bvFTD versus PPD, Panel-NfL, NPTX2. B bvFTD versus AD, Panel-NfL, SNAP25, Ng, GluR4. AUCs are shown for biomarkers alone. bvFTD, behavioral variant frontotemporal dementia, PPD, primary psychiatric disorders; AD, Alzheimer’s disease; AUC, area under curve; ROC, receiver operating characteristics; NfL, neurofilament; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4

Full size image

bvFTD versus PPD

Among the synaptic biomarkers, NPTX2 had the highest AUC (AUC= 0.72, CI: 0.63–0.81, p < 0.001) to discriminate bvFTD from PPD. SNAP25, Ng, and GluR4 were not predictive of the diagnostic group. The AUC of NfL (AUC= 0.95, CI: 0.91–0.99, p < 0.001) was higher than that of the synaptic proteins. The biomarker panel to differentiate bvFTD from PPD, selected using Wald’s backward selection among the candidate biomarkers consisted of NfL and NPTX2 (AUC =0.96, CI: 0.93–0.99, p < 0.001).

bvFTD versus AD

Among the synaptic biomarkers, SNAP25 had the highest AUC (AUC = 0.79, CI: 0.70–0.87, p < 0.001), followed by Ng (AUC = 0.69, CI: 0.59–0.79, p = 0.001) and NPTX2 (AUC = 0.63, CI: 0.52–0.73, p = 0.019) to discriminate bvFTD from AD. GluR4 was not predictive between these two diagnostic groups. The AUC of NfL (AUC= 0.75, CI: 0.65–0.84, p < 0.001) was higher than all synaptic biomarkers except SNAP25. The selected biomarker panel using Wald’s backward selection method, for differential diagnosis of bvFTD from AD, consisted of NfL, SNAP25, Ng, and GluR4 (AUC = 0.86, CI: 0.79–0.92, p < 0.001).

Associations of the CSF synaptic biomarkers and NfL with cognition and disease severity

The correlations of the CSF biomarkers with cognition and disease severity are shown in Fig. 3, Supplementary Figure 1, and Supplementary Figure 2. There were no associations between any of the synaptic markers and social cognition (Ekman 60 faces test) or disease severity in bvFTD. Lower CSF concentrations of NPTX2 (Pearson’s r = 0.29, p = 0.036) and GluR4 (Pearson’s r = 0.34, p = 0.014) were weakly associated with worse performance of total cognitive score in bvFTD. Furthermore, lower GluR4 concentrations were also moderately associated with worse absolute MMSE scores in bvFTD (Pearson’s r = 0.41, p = 0.002) and weakly associated with worse executive functioning (Pearson’s r = 0.36, p = 0.011). In patients with AD, lower NPTX2 concentrations were moderately associated with worse performance scores on the cognitive domain language (Pearson’s r = 0.43, p < 0.001). Counterintuitively, in AD, higher CSF SNAP25 associated weakly with better performance on the domain attention (Pearson’s r = 0.30, p = 0.022). No significant correlations were detected between the CSF biomarkers and cognitive scores in patients with PPD or in controls. In the bvFTD and PPD groups, there were no significant correlations between cognitive scores and the generated biomarker panels (bvFTD_PPD, bvFTD_AD, Supplementary Figure 1). In the AD group, the panel bvFTD_AD correlated weakly with attention (Pearson’s r = − 0.30, p = 0.026), and in controls, the panel bvFTD_PPD correlated moderately with visuospatial functioning (Pearson’s r = − 0.42, p = 0.012).

Fig. 3
figure 3

Correlation matrix of the fluid biomarkers to cognitive test performance and social test scores in patients with bvFTD, PPD, AD, and controls. The associations are shown as Pearson’s partial correlations, controlling for age. bvFTD, behavioral variant frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease; NfL, neurofilament light; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; MMSE, mini-mental state examination; FTLD-CDR, frontotemporal lobe dementia-cognitive dementia rating. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Discussion

In this study, we found differential concentrations of CSF synaptic markers between bvFTD, PPD, AD, and controls in which reduced NPTX2 concentrations were bvFTD specific, and increased concentrations of SNAP25 and Ng were AD specific. Adding NPTX2 to NfL in the biomarker panel to distinguish bvFTD and PPD patients provided added diagnostic value, although limited. Synaptic biomarker concentrations did not correlate with social cognition nor disease severity in FTD and showed weak correlations with cognitive performance. These results indicate that NPTX2, alongside NfL, may provide further insights into bvFTD pathophysiology, although it is relatively less suitable clinically as a diagnostic biomarker.

NfL is a reliable biomarker of neuroaxonal damage and is used for the diagnosis (although limited due to its non-disease specificity), prognosis, and monitoring of treatment response in several neurodegenerative conditions [38]. Several clinical reports have asserted the association of NfL with grey matter and hippocampal atrophy, neuronal impairment, and loss of cognition in neurodegenerative dementias [17,18,19,20]. Accumulating clinical evidence further suggests that NfL is a promising biomarker in clinical settings to differentiate patients with bvFTD from PPD [39]. However, high levels of NfL are not specific to bvFTD as this biomarker can be strongly elevated in several other neurodegenerative conditions as well [2, 40, 41]. Furthermore, clinical reports suggest that synaptic dysfunction precedes atrophy in patients with FTD [11, 14], which highlights the need for novel biomarkers that may aid in earlier and more accurate diagnosis of bvFTD over PPD.

Our findings of lower NPTX2 concentrations in sporadic FTD compared with PPD and controls are in line with our previous pilot study and with a recent study among patients with genetic forms of FTD, in which symptomatic mutation carriers showed lower concentrations of CSF NPTX2 compared with controls [13]. NPTX2 has also recently been identified as a promising biomarker for progression in genetic FTD [13]. NPTX2 is involved in the formation and stabilization of synapses, facilitating proper communication between neurons in the brain, and plays a crucial role in synaptic function and plasticity [42]. Studies have shown decreased synaptic density in the brains of FTD patients, particularly in brain regions affected by the disease including the salient network, inducing the characteristic impaired social cognition that is a hallmark feature of FTD [11]. Experimental evidence further suggests that downregulation of NPTX2 may lead to increased complement-mediated microglial activation, thereby causing abnormal elimination of synapses [43]. The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42]. Further investigation of NPTX2 and its mechanisms in FTD could provide valuable insights into the disease mechanisms and potentially lead to the development of novel therapeutic strategies targeting synaptic dysfunction.

While it has been reported elsewhere that CSF concentration of GluR4 is decreased in patients with mood disorder and schizophrenia compared with healthy controls [16], we did not find any diagnostic significance of this biomarker in this cohort. This might be due to our heterogeneous sample of PPD, including various subtypes such as mood disorders, personality disorders, autism spectrum disorder, anxiety disorder, functional disorder, schizophrenia, and other psychiatry, of which individual group levels did not reach statistically significant thresholds of lower GluR4.

Synaptic pathology is a shared mechanism across diseases, yet evidence presented here and elsewhere indicates that synaptic proteins participate differentially in various disease pathogeneses, underscoring the distinct impairments in synaptic functionality across diseases. For example, the AD-specific increase of CSF SNAP25 and Ng compared with bvFTD that we reported, corroborates previous findings [44, 45]. Ng is a postsynaptic protein that is important for maintaining synaptic plasticity and regulating calcium ion influxes, while SNAP25 is a presynaptic protein that plays a crucial role in synaptic vesicle fusion and neurotransmitter release, and both these proteins have been shown to play a key role in AD disease pathophysiology, although they may be less clinically relevant for FTD [10, 45,46,47,48]. While brain regions affected in AD, i.e., the hippocampus and cortex have a high expression of Ng, the anatomical distribution of SNAP25 is not well known, although it is expressed in the cortex [49,50,51,52]. Thus, a possible hypothesis for the increased concentrations of synaptic proteins SNAP25 and Ng in AD but not in bvFTD could be due to the topography of brain atrophy they reflect [45].

In our cohort, bvFTD patients performed worse on social cognition testing compared with PPD, but no association was found with CSF synaptic markers which might be due to the limited test scores available per diagnostic group, i.e., only 13 for bvFTD and 9 for PPD. A previous study, using [18F]UCBH-PET as a tracer for synaptic vesicle protein 2A (SV2A) which reflects synaptic density, showed a trend for synaptic loss in the temporal social brain in bvFTD, highlighting the clinical relevance of synaptopathy in disease pathophysiology of FTD [14]. Further studies assessing CSF synaptic markers might elucidate if SV2A is a superior synaptic marker in CSF correlating with social cognition in larger patient groups.

The association of the synaptic biomarkers with other cognitive functioning was absent or only moderate to weak in bvFTD and AD, while there were no correlations found in patients with PPD or with controls. Moreover, we did not detect any association of the synaptic proteins or NfL with FTLD-CDR disease severity scores [53, 54]. One plausible reason could be that the cohort included a homogenous sample of bvFTD patients with mild to moderate bvFTD disease severity (FTLD-CDR ≤ 16). The direction of correlation detected in the AD group between SNAP25 and attention was counterintuitive, and thus follow-up studies with greater statistical power are necessary to evaluate these findings.

The strengths of this study lie in including the assessment of concentrations of CSF synaptic proteins involved in several synaptic functions both upstream and downstream of the synapse, providing insight into pathophysiological mechanisms. Additionally, we included a well-phenotyped diverse PPD sample as a comparative group, which is the most important and clinically challenging to differentially diagnose from bvFTD, resembling clinical practice. There are also some limitations. For example, the odds ratios of the synaptic biomarkers for diagnostic distinction of bvFTD versus PPD and AD were modest and the clinical relevance of these biomarkers, particularly NPTX2, demands to be evaluated in larger cohorts. Since the PPD sample was heterogeneous, disease-specific synaptic concentrations in PPD could not be assessed and should be included in future studies. Furthermore, the sample sizes for cognitive test scores were limited, such as for social cognition (Ekman 60 faces test), disease severity (FTLD-CDR), and the domain visuospatial functioning.

Conclusions

We conclude that synaptic biomarker NPTX2 has additional, although limited diagnostic value to NfL in the differential diagnosis of bvFTD versus PPD. Our findings contribute insight into disease-specific mechanisms in bvFTD, by showing the bvFTD-specific decrease in concentrations of NPTX2. Furthermore, given that NfL likely reflects neuronal atrophy [17, 18], it is a clinically relevant biomarker at a progressed stage of the disease. Further investigation of NPTX2 and its mechanisms in bvFTD could provide valuable insights into the disease mechanisms for early diagnosis and prognosis, as well as potentially lead to the development of novel therapeutic strategies.

Availability of data and materials

Anonymized data can be made available upon reasonable request and consultation with the involved authorities. Additional datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

AD:

Alzheimer’s disease

ANCOVA:

Analysis of covariance

ANOVA:

Analysis of variance

AUC:

Area under curve

bvFTD:

Behavioral variant frontotemporal dementia

CSF:

Cerebrospinal fluid

CV:

Coefficient of variation

FAB:

Frontal assessment battery

FTD:

Frontotemporal dementia

FTLD-CDR:

Frontotemporal lobar degeneration-modified clinical dementia rating

GDS:

Geriatric depression scale

GluR4:

Glutamate receptor 4

MMSE:

Mini-mental state examination

NfL:

Neurofilament light

Ng:

Neurogranin

NPTX2:

Neuronal pentraxin 2

OR:

Odds ratio

PPD:

Primary psychiatric disorders

RAVLT:

Rey auditory verbal learning test

ROC:

Receiver operating characteristics

SNAP25:

Synaptosomal-associated protein of 25 kDa

TMT:

Trail making test

VAT:

Visual association test

VOSP:

Visual object and space perception

References

  1. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25(2):130–7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022;18(11):2292–307.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632–50.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease; rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. The Journal of clinical psychiatry. 2011;72(2):126.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, et al. Diagnostic accuracy of MRI and additional [18F] FDG-PET for behavioral variant frontotemporal dementia in patients with late onset behavioral changes. Journal of Alzheimer’s Disease. 2016;53(4):1287–97.

    Article  Google Scholar 

  6. Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta neuropathologica. 2018;135(2):213–26.

    Article  CAS  PubMed  Google Scholar 

  7. Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. Journal of neurochemistry. 2016;138:54–70.

    Article  CAS  PubMed  Google Scholar 

  8. Lashley T, Rohrer JD, Mead S, Revesz T. An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathology and applied neurobiology. 2015;41(7):858–81.

    Article  PubMed  Google Scholar 

  9. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nature Reviews Neurology. 2012;8(8):423–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cervantes González A, Irwin DJ, Alcolea D, McMillan CT, Chen-Plotkin A, Wolk D, et al. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration. 2022;17(1):1–12.

    Article  Google Scholar 

  11. Salmon E, Bahri MA, Plenevaux A, Becker G, Seret A, Delhaye E, et al. In vivo exploration of synaptic projections in frontotemporal dementia. Scientific reports. 2021;11(1):1–10.

    Article  ADS  Google Scholar 

  12. Sogorb-Esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, Russell LL, et al. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimer’s research & therapy. 2022;14(1):1–12.

    Google Scholar 

  13. Van Der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(6):612–21.

    Article  Google Scholar 

  14. Malpetti M, Jones PS, Cope TE, Holland N, Naessens M, Rouse MA, et al. Synaptic loss in frontotemporal dementia revealed by [11C] UCB-J positron emission tomography. Ann Neurol. 2023;93(1):142–54. https://doi.org/10.1002/ana.26543.

  15. Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, In ‘t Veld S, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15(1):62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gómez de San José N, Goossens J, Al Shweiki MR, Halbgebauer S, Oeckl P, Steinacker P, et al. Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. J Psychiatr Res. 2022;156:390–97. https://doi.org/10.1016/j.jpsychires.2022.10.010.

  17. Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease. Alzheimers Dement (Amst). 2020;12(1):e12005. https://doi.org/10.1002/dad2.12005.

    PubMed  PubMed Central  Google Scholar 

  18. Kartau M, Melkas S, Kartau J, Arola A, Laakso H, Pitkänen J, et al. Neurofilament light level correlates with brain atrophy, and cognitive and motor performance. Front Aging Neurosci. 2022;14: 939155.

    Article  PubMed  Google Scholar 

  19. Walia N, Eratne D, Loi SM, Farrand S, Li Q-X, Malpas CB, et al. Cerebrospinal fluid neurofilament light and cerebral atrophy in younger-onset dementia and primary psychiatric disorders. Intern Med J. 2023;53(9):1564–69. https://doi.org/10.1111/imj.15956.

  20. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199. https://doi.org/10.3389/fnins.2021.679199.

  22. Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020;267(1):162–7.

    Article  CAS  PubMed  Google Scholar 

  23. Varhaug KN, Torkildsen Ø, Myhr KM, Vedeler CA. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019;10:338. https://doi.org/10.3389/fneur.2019.00338.

  24. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology: Nature Publishing Group; 2018. p. 577–89.

    Google Scholar 

  25. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimer’s & Dementia. 2017;13(3):296–311.

    Article  Google Scholar 

  26. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer’s disease. 2014;41(1):313–27.

    Article  Google Scholar 

  27. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Journal of Alzheimer’s Disease. 2018;62(3):1091–111.

    Article  PubMed Central  Google Scholar 

  28. Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90(2): e149.

    Article  PubMed  Google Scholar 

  29. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Alzheimers Dis. 2018;62(3):1091–1111. https://doi.org/10.3233/JAD-170850.

  30. Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2018;10:563–72.

    PubMed Central  Google Scholar 

  31. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.

    Article  PubMed  PubMed Central  Google Scholar 

  33. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). American Psychiatric Publishing, Inc.. 2013. https://doi.org/10.1176/appi.books.9780890425596.

  34. Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131(11):2957–68.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Das S, Dewit N, Jacobs D, Pijnenburg YAL, In ‘t Veld SGJG, Coppens S, et al. A novel neurofilament light chain ELISA validated in patients with Alzheimer’s disease, frontotemporal dementia, and subjective cognitive decline, and the evaluation of candidate proteins for immunoassay calibration. Intern J Mol Sci. 2022;23(13):7221.

    Article  CAS  Google Scholar 

  36. Bolsewig K, Hok-A-Hin YS, Sepe FN, Boonkamp L, Jacobs D, Bellomo G, et al. A combination of neurofilament light, glial fibrillary acidic protein, and neuronal pentraxin-2 discriminates between frontotemporal dementia and other dementias. Journal of Alzheimer’s Disease. 2022;90:363–80.

    Article  CAS  PubMed Central  Google Scholar 

  37. Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, Blennow K, Chiasserini D, Engelborghs S, et al. A practical guide to immunoassay method validation. Front Neurol. 2015;19(6):179.

    Google Scholar 

  38. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol, Neurosurg Psychiatry: BMJ Publishing Group. 2019;90(8):870–81.

    Article  Google Scholar 

  39. Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, et al. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings. Alzheimer’sDement. 2022;18(11):2218–33.

    Google Scholar 

  40. Ulugut H, Pijnenburg YAL. Frontotemporal dementia: past, present, and future. Alzheimers Dement. 2023;19(11):5253–63.

    Article  PubMed  Google Scholar 

  41. Illán-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and alzheimer disease. Neurology. 2021;96(5):e671–83.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Gómez de San José N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm (Vienna). 2022;129(2):207–30. https://doi.org/10.1007/s00702-021-02411-2.

  43. Zhou J, Wade SD, Graykowski D, Xiao M-F, Zhao B, Giannini LAA, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Science Translational Medicine. 2023;15(689):eadf0141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer’s Research & Therapy. 2022;14(1):58.

    Article  Google Scholar 

  45. Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia. Alzheimer’s ResTher. 2019;11(1):105.

    CAS  Google Scholar 

  46. Wang C, Tu J, Zhang S, Cai B, Liu Z, Hou S, et al. Different regions of synaptic vesicle membrane regulate VAMP2 conformation for the SNARE assembly. Nature Communications. 2020;11(1):1531.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  47. Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB Journal. 2016;30(12):4141–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener. 2014;9:53.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica. 2018;136(3):363–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10(12):3782–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yamamori S, Itakura M, Sugaya D, Katsumata O, Sakagami H, Takahashi M. Differential expression of SNAP-25 family proteins in the mouse brain. Journal of Comparative Neurology. 2011;519(5):916–32.

    Article  CAS  PubMed  Google Scholar 

  52. Glavan G, Schliebs R, Živin M. Synaptotagmins in neurodegeneration. The Anatomical Record. 2009;292(12):1849–62.

    Article  CAS  PubMed  Google Scholar 

  53. Diehl-Schmid J, Pohl C, Ruprecht C, Wagenpfeil S, Foerstl H, Kurz A. The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia. Archives of Clinical Neuropsychology. 2007;22(4):459–64.

    Article  PubMed  Google Scholar 

  54. Research Australia N, Piguet AO, Hornberger M, Mioshi E, Hodges FmedSci JR, Hodges J, et al. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:162–72.

    Article  Google Scholar 

Download references

Acknowledgements

Clinical CSF samples were requested from the Amsterdam Dementia Cohort located at the Amsterdam University Medical Centre. Research of Alzheimer’s Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. There was no financial or material support for this research, and there were no any potential conflicts of interest. We thank the FTD expert group for their valuable input on the design of the study and the interpretation of the results. We would like to thank Charlotte De Rocker for her suggestions and critical review of the manuscript.

Funding

This research has received funding from the European Union’s Horizon 2020 research and innovation Marie Curie program “MIRIADE” under grant agreement number 860197. Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. C.E.T. is the recipient of the ZonMW-funded PRODIA project (#ZonMW 733050206). YALP received funding from Stichting Dioraphte, although this funding source had no role in the design, practice, or analysis of this study.

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Neurochemistry Laboratory, Amsterdam, UMC location VrijeUniversiteit Amsterdam, Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands

    Shreyasee Das, Bram Bongers, Charlotte E. Teunissen & Inge M. W. Verberk

  2. Neurology, Amsterdam UMC location VUmc, Alzheimer Center Amsterdam, VrijeUniversiteit Amsterdam, De Boelelaan 1118, Amsterdam, 1081 HZ, The Netherlands

    Marie-Paule E. van Engelen, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Charlotte E. Teunissen & Inge M. W. Verberk

  3. Amsterdam Neuroscience, Neurodegeneration, De Boelelaan 1085, Amsterdam, 1081 HV, The Netherlands

    Marie-Paule E. van Engelen, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Charlotte E. Teunissen & Inge M. W. Verberk

  4. ADx NeuroSciences, Technologiepark-Zwijnaarde 6, 9052, Gent, Belgium

    Shreyasee Das, Julie Goossens, Dirk Jacobs & Eugeen Vanmechelen

Authors
  1. Shreyasee Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Paule E. van Engelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Goossens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dirk Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bram Bongers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jay L. P. Fieldhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yolande A. L. Pijnenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Charlotte E. Teunissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eugeen Vanmechelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Inge M. W. Verberk
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.D. performed development and analytical validations of the immunoassays, clinical sample measurements, data analysis, and figure preparation, and wrote the first draft of the manuscript. M.P.E.V.E. performed clinical cohort design and sample selection, clinical assessments of the patients and procured clinical data, data analysis, and wrote the first draft of the manuscript. J.G. performed development and analytical validations of the immunoassays and reviewed and critiqued the manuscript. D.J. performed development and analytical validations of the immunoassays. B.B. performed analytical validations of the immunoassays, clinical sample measurements, and reviewed the manuscript. J.L.P.F. provided critical information regarding clinical neuropsychological evaluations and reviewed the manuscript. Y.A.L.P. was responsible for project supervision, clinical cohort design, and reviewed the manuscript. C.E.T. was responsible for project supervision, clinical cohort design, and reviewed the manuscript. E.V. was responsible for project supervision, clinical cohort design, and reviewed the manuscript. I.M.W.V. was responsible for project supervision, provided assistance with data analysis techniques, as well as extensive critical review of the manuscript. S.D. and M.P.E.V.E. have contributed equally to this manuscript. All authors have approved the submission of this manuscript and consent to its publication. All authors reviewed the manuscript.

Corresponding author

Correspondence to Inge M. W. Verberk.

Ethics declarations

Ethics approval and consent to participate

All clinical CSF samples were requested via the Amsterdam Dementia Cohort biobank. The study was approved by the Medical Ethical Committee of Amsterdam University Medical Center. All participants provided informed consent and the study has been carried out by the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

S.D., and J.G., are employees of ADx NeuroSciences, Gent, Belgium. E.V. is the co-founder of ADx NeuroSciences. D.J. is a former employee of ADx NeuroSciences, Gent, Belgium, and is recently retired. C.E.T. has a collaboration contract with ADx NeuroSciences, Quanterix, and Eli Lilly, and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is the editor of a Neuromethods book Springer. All the other authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: 

Supplementary Figure 1. Correlation matrix of the fluid biomarkers to cognitive test performance and social test scores in patients with bvFTD, PPD, AD, and controls. The associations are shown as Pearson’s partial correlations, controlling for age. bvFTD: behavioral variant frontotemporal dementia, PPD: primary psychiatric disorders, AD: Alzheimer’s disease, NfL: neurofilament light, SNAP25: synaptosomal associated protein 25, Ng: neurogranin, NPTX2: neuronal pentraxin 2, GluR4: Glutamate receptor 4, MMSE: mini-mental state examination, FTLD-CDR: frontotemporal lobe dementia- cognitive dementia rating. Panel bvFTD_PPD: NfL, NPTX2, Panel bvFTD_AD: NfL, SNAP25, Ng, GluR4 (both differential diagnostic panels selected using backward logistic regression models).*p <0.05, **p <0.01, ***p <0.001

Additional file 2: Supplementary Figure 2.

 Visualization of correlations between biomarkers and cognitive test scores. A) bvFTD: NPTX2 versus total cognitive score, B) bvFTD: GluR4 versus total cognitive score, C) bvFTD: GluR4 versus executive functioning, D) bvFTD: GluR4 versus MMSE scores, E) AD: NPTX2 versus language and F) AD: SNAP25 versus attention. bvFTD: behavioral variant frontotemporal dementia, AD: Alzheimer’s diseaseSNAP25: synaptosomal associated protein 25, NPTX2: neuronal pentraxin 2, GluR4: Glutamate receptor 4, MMSE: mini-mental state examination.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Das, S., van Engelen, MP.E., Goossens, J. et al. The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease. Alz Res Therapy 16, 34 (2024). https://doi.org/10.1186/s13195-024-01409-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13195-024-01409-8

Keywords

Alzheimer's Research & Therapy

ISSN: 1758-9193